- Home
- IEP vs KRYS Comparison
IEP vs KRYS Comparison
Compare IEP & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IEP
- KRYS
- Stock Information
- Founded
- IEP 1987
- KRYS 2015
- Country
- IEP United States
- KRYS United States
- Employees
- IEP N/A
- KRYS N/A
- Industry
- IEP Auto Parts:O.E.M.
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IEP Consumer Discretionary
- KRYS Health Care
- Exchange
- IEP Nasdaq
- KRYS Nasdaq
- Market Cap
- IEP 4.7B
- KRYS 4.7B
- IPO Year
- IEP 1987
- KRYS 2017
- Fundamental
- Price
- IEP $8.85
- KRYS $196.65
- Analyst Decision
- IEP
- KRYS Strong Buy
- Analyst Count
- IEP 0
- KRYS 9
- Target Price
- IEP N/A
- KRYS $214.22
- AVG Volume (30 Days)
- IEP 913.0K
- KRYS 316.5K
- Earning Date
- IEP 11-05-2025
- KRYS 11-03-2025
- Dividend Yield
- IEP 22.60%
- KRYS N/A
- EPS Growth
- IEP N/A
- KRYS 275.72
- EPS
- IEP N/A
- KRYS 6.66
- Revenue
- IEP $9,524,000,000.00
- KRYS $373,164,000.00
- Revenue This Year
- IEP N/A
- KRYS $34.33
- Revenue Next Year
- IEP $0.69
- KRYS $48.04
- P/E Ratio
- IEP N/A
- KRYS $29.65
- Revenue Growth
- IEP N/A
- KRYS 54.51
- 52 Week Low
- IEP $7.27
- KRYS $122.80
- 52 Week High
- IEP $13.60
- KRYS $212.98
- Technical
- Relative Strength Index (RSI)
- IEP 63.79
- KRYS 59.19
- Support Level
- IEP $7.96
- KRYS $194.92
- Resistance Level
- IEP $9.32
- KRYS $212.98
- Average True Range (ATR)
- IEP 0.20
- KRYS 8.35
- MACD
- IEP 0.10
- KRYS -0.17
- Stochastic Oscillator
- IEP 64.44
- KRYS 42.14
About IEP Icahn Enterprises L.P.
Icahn Enterprises LP provides diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.